Literature DB >> 2675714

[Prognostic factors of hypereosinophilic syndrome. Study of 40 cases].

C Lefebvre1, O Bletry, P Degoulet, L Guillevin, M Bentata-Pessayre, D u Le Thi Huong, P Godeau.   

Abstract

Forty patients with hypereosinophilic syndrome (HES), defined according to the criteria established by Chusid et al., were studied retrospectively in order to determine the prognostic factors in this heterogeneous disease. A myeloproliferative syndrome (MPS) was diagnosed 17 times when splenomegaly and/or a greater than 5 times the normal vitamin B12, level existed. Cutaneous-visceral involvement was almost always present (95%), but could appear after several years of evolution. Twenty-three patients had cardiac involvement, determined by clinical, radiological, electrocardiographic and echocardiographic examinations; 12 of these had endomyocardiac fibrosis. The overall survival rate was 80% at 5 years and 42% at 10 and 15 years. Among the factors evaluated that are capable of influencing this survival, 5 were found to impair the prognosis; presence of an MPS; non-response of the hypereosinophilia to corticoids; existence of a cardiopathy; being male; and an elevated maximum eosinophilia; the last two factors were significantly associated with the cardiopathy. Because hematological or cardiac anomalies are not always present at the time of the first examination, HES patients require very close surveillance.

Entities:  

Mesh:

Year:  1989        PMID: 2675714

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN: 0003-410X


  15 in total

Review 1.  Eosinophilic myeloproliferative disorders.

Authors:  Amy D Klion
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Löffler endocarditis without peripheral eosinophilia.

Authors:  G H Wasmeier; D Ropers; A Dimmler; T Fischlein; W G Daniel
Journal:  Clin Res Cardiol       Date:  2007-01-22       Impact factor: 5.460

Review 3.  Advances in diagnosis and treatment of eosinophilia.

Authors:  Javed Sheikh; Peter F Weller
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

Review 4.  Idiopathic hypereosinophilic syndrome in children: 3 cases with review of literature.

Authors:  Jayashree Kanthila; Nalini Bhaskaranand
Journal:  Indian J Pediatr       Date:  2012-06-28       Impact factor: 1.967

5.  Hypereosinophilia in Children and Adults: A Retrospective Comparison.

Authors:  Kelli W Williams; JeanAnne Ware; Annalise Abiodun; Nicole C Holland-Thomas; Paneez Khoury; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2016-04-27

6.  Pediatric Hypereosinophilia: Characteristics, Clinical Manifestations, and Diagnoses.

Authors:  Dara Burris; Chen E Rosenberg; Justin T Schwartz; Yin Zhang; Michael D Eby; J Pablo Abonia; Patricia C Fulkerson
Journal:  J Allergy Clin Immunol Pract       Date:  2019-05-22

Review 7.  Clinical overview of cutaneous features in hypereosinophilic syndrome.

Authors:  Sabine Gisela Plötz; Bettina Hüttig; Birgit Aigner; Christian Merkel; Knut Brockow; Cezmi Akdis; Ulf Darsow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

8.  Large apical thrombus in a patient with persistent heart failure and hypereosinophilia: Löffler endocarditis.

Authors:  A Altug Cincin; Beste Ozben; M Azra Tanrikulu; Ozdil Baskan; Mehmet Agirbasli
Journal:  J Gen Intern Med       Date:  2008-07-10       Impact factor: 5.128

9.  Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.

Authors:  Srdan Verstovsek; Ayalew Tefferi; Hagop Kantarjian; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Pat Ault; Carlos Bueso-Ramos; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

10.  A patient with oeosinophilic gastroenteritis and severe malnutrition improved with home parenteral nutrition.

Authors:  Lidia Santarpia; Rosario Cuomo; Luigi Camera; Lucia Alfonsi; Franco Contaldo; Fabrizio Pasanisi
Journal:  BMJ Case Rep       Date:  2010-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.